mRNA
Showing 26 - 50 of 3,098
Respiratory Syncytial Virus Infection Trial in Puerto Rico, United States (RSV mRNA LNP CL-0059 Low dose, RSV mRNA LNP CL-0137
Recruiting
- Respiratory Syncytial Virus Infection
- RSV mRNA LNP CL-0059 Low dose
- +6 more
-
Hollywood, Florida
- +4 more
Jan 17, 2023
Glioblastoma Trial in Belgium, Germany, Netherlands (CV09050101 mRNA vaccine (CVGBM) 12 µg, CV09050101 mRNA vaccine (CVGBM) 25
Recruiting
- Glioblastoma
- CV09050101 mRNA vaccine (CVGBM) 12 μg
- +5 more
-
Woluwe-Saint-Lambert, Brussels, Belgium
- +14 more
Jul 12, 2023
Seasonal Influenza Trial in United States (mRNA-1030, mRNA-1020, mRNA-1010)
Completed
- Seasonal Influenza
- mRNA-1030
- +3 more
-
Phoenix, Arizona
- +14 more
Dec 5, 2022
SARS-CoV-2 Trial in United States (mRNA-1283, mRNA-1273, Placebo)
Active, not recruiting
- SARS-CoV-2
- mRNA-1283
- +2 more
-
Chandler, Arizona
- +4 more
Sep 22, 2022
COVID-19 Trial in Paris (Lymph node aspiration / Blood sampling)
Recruiting
- COVID-19
- Lymph node aspiration / Blood sampling
-
Paris, FranceGH Broca-Cochin-Hôtel-Dieu CIC 1417 Cochin-Pasteur
Jul 19, 2023
HIV-1-infection Trial in Kigali, Johannesburg (eOD-GT8 60mer mRNA Vaccine (100µg))
Active, not recruiting
- HIV-1-infection
- eOD-GT8 60mer mRNA Vaccine (100µg)
-
Kigali, Rwanda
- +1 more
Sep 9, 2022
SARS-CoV-2 Trial in United States (mRNA-1273.211, mRNA-1273, mRNA-1273.617.2)
Active, not recruiting
- SARS-CoV-2
- mRNA-1273.211
- +6 more
-
Sacramento, California
- +22 more
Nov 16, 2022
SARS-CoV-2 Trial in Nanjing (SARS-CoV-2 Bivalent mRNA Vaccine, Recombinant SARS-CoV-2 vaccine, Saline)
Not yet recruiting
- SARS-CoV-2
- SARS-CoV-2 Bivalent mRNA Vaccine
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Center for Disease Control and Prevention
Jul 7, 2023
SARS-CoV-2 Trial (SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high
Not yet recruiting
- SARS-CoV-2
- SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose
- +2 more
- (no location specified)
Dec 1, 2022
Cytomegalovirus Infection Trial in Boston (mRNA-1647, Placebo)
Not yet recruiting
- Cytomegalovirus Infection
- mRNA-1647
- Placebo
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 4, 2023
Vaccine Reaction, COVID-19 Trial in Paris (Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech), VidPrevtyn® Beta
Not yet recruiting
- Vaccine Reaction
- COVID-19
- Comirnaty® BNT162b2 /Omicron BA.4-5 vaccine (Pfizer-BioNTech)
- VidPrevtyn® Beta vaccine (Sanofi/GSK)
-
Paris, FranceCIC 1417 Cochin-Pasteur
Feb 28, 2023
SARS-CoV-2 Trial in Bengbu (SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA
Active, not recruiting
- SARS-CoV-2
- SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose
- +2 more
-
Bengbu, Anhui, ChinaFirst Affiliated Hospital Bengbu Medical College
Jan 3, 2023
Lyme Disease Trial in United States (mRNA-1975, mRNA-1982, Placebo)
Recruiting
- Lyme Disease
- mRNA-1975
- +2 more
-
Milford, Connecticut
- +19 more
Jul 26, 2023
Pancreatic Cancer Trial in Shanghai (Adebrelimab, mRNA tumor vaccines)
Not yet recruiting
- Pancreatic Cancer
- Adebrelimab
- mRNA tumor vaccines
-
Shanghai, Shanghai, ChinaDepartment of Pancreatic Surgery, Fudan University Shanghai Canc
Dec 4, 2023
MYocarditis and/or Pericarditis Following mRNA COVID-19
Recruiting
- Myocarditis
- +3 more
- Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire
- Baseline Quality of Life questionnaire
-
Vancouver, British Columbia, CanadaVancouver General Hospital
Oct 24, 2023
Influenza, COVID-19, Influenza Immunogencity Trial in United States (Simultaneous Vaccination (Influenza Vaccine and mRNA COVID
Not yet recruiting
- Influenza
- +3 more
- Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)
- +2 more
-
Phoenix, Arizona
- +7 more
Aug 30, 2023
Influenza Immunization Trial in Australia (H3 mRNA / LNP Vaccine, Quadrivalent recombinant influenza Vaccine (RIV4))
Recruiting
- Influenza Immunization
- H3 mRNA / LNP Vaccine
- Quadrivalent recombinant influenza Vaccine (RIV4)
-
Herston, Queensland, Australia
- +3 more
May 1, 2023
SARS-CoV-2 Trial in Chengdu (RBMRNA-176, Placebo)
Active, not recruiting
- SARS-CoV-2
- RBMRNA-176
- Placebo
-
Chengdu, Sichuan, ChinaChengdu Xinhua Hospital affiliated to North Sichuan Medical Coll
Jun 12, 2023
COVID-19, COVID-19 Immunisation Trial in Decatur, Bethesda, Seattle (mRNA-1273)
Completed
- COVID-19
- COVID-19 Immunisation
- mRNA-1273
-
Decatur, Georgia
- +2 more
Jan 26, 2023
Digestive System Tumors Trial in Hangzhou (iNeo-Vac-R01)
Recruiting
- Digestive System Neoplasms
- iNeo-Vac-R01
-
Hangzhou, Zhejiang, ChinaDepartment of General Surgery, Institute of Minimally Invasive S
Sep 8, 2023
SARS-CoV-2 Trial in Islamabad (SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021), 0.9% sodium chloride solution)
Recruiting
- SARS-CoV-2
- SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)
- 0.9% sodium chloride solution
-
Islamabad, PakistanSindh Infectious Diseases Hospital & Research Center Dow Univers
Apr 16, 2023
SARS-CoV2 Infection, Coronavirus Infection Trial in Hamilton (mRNA- COVID-19, Prevnar13)
Not yet recruiting
- SARS-CoV2 Infection
- Coronavirus Infection
- mRNA- COVID-19
- Prevnar13
-
Hamilton, Ontario, CanadaMcMaster University
Jun 29, 2022
Nipah Virus Infection Trial run by the NIAID (mRNA -1215)
Recruiting
- Nipah Virus Infection
- mRNA -1215
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 30, 2022
Influenza Trial in Saint Louis (mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine)
Recruiting
- Influenza
- mRNA-1010
- +3 more
-
Saint Louis, MissouriWashington University in St. Louis
Nov 4, 2022
Melanoma Trial (V940, Pembrolizumab, Placebo)
Not yet recruiting
- Melanoma
- V940
- +2 more
- (no location specified)
Jul 12, 2023